Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...
 
 

The Role of CYP2C19 Pharmacogenomic Testing in Appropriate Antiplatelet Therapy


Date: Feb 23, 2021 01:00 PM - 02:00 PM

Fee

$0.00

CE Hours

1.00

CE Units

0.100

Registration closes on Apr 23, 2021 01:00 AM

Activity Type

  • Knowledge

Target Audience(s)

  • Pharmacists
  • Pharmacy Students

Accreditation(s)

Accreditation Council for Pharmacy Education
Accreditation Statement: Howard University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

 

 

   

Objectives

  • Define CYP2C19 polymorphisms and explain the impact on antiplatelet therapy used for coronary artery disease management
  • Describe the process of implementing CYP2C19 pharmacogenomic testing to optimize antiplatelet therapy
  • Explain the role of a multidisciplinary health care team in implementing a CYP2C19 pharmacogenetic testing service

Speaker(s)/Author(s)

Cynthea Lee, Pharm.D., MS, BCPS
Assistant Clinical Professor, Howard University

Divita Singh, PharmD, BCPS

Activity Number

0010-0000-21-001-L01-P
Date: 02/23/21
Time: 01:00 PM - 02:00 PM

CE Hours

1.00

Location

Webinar